Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Gross Profit: 2024-2025

Historic Gross Profit for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to $39.8 million.

  • Day One Biopharmaceuticals' Gross Profit fell 57.56% to $39.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.7 million, marking a year-over-year change of. This contributed to the annual value of $131.2 million for FY2024, which is N/A change from last year.
  • Day One Biopharmaceuticals' Gross Profit amounted to $39.8 million in Q3 2025, which was up 17.36% from $33.9 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Gross Profit high stood at $93.8 million for Q3 2024, and its period low was $8.2 million during Q2 2024.
  • For the 2-year period, Day One Biopharmaceuticals' Gross Profit averaged around $39.3 million, with its median value being $32.3 million (2025).
  • Over the last 5 years, Day One Biopharmaceuticals' Gross Profit had its largest YoY gain of 313.92% in 2025, and its largest YoY loss of 57.56% in 2025.
  • Quarterly analysis of 2 years shows Day One Biopharmaceuticals' Gross Profit stood at $29.2 million in 2024, then slumped by 57.56% to $39.8 million in 2025.
  • Its last three reported values are $39.8 million in Q3 2025, $33.9 million for Q2 2025, and $30.8 million during Q1 2025.